The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Recruiting now · Phase 2/Phase 3

Conditions studied: Multiple Myeloma

In brief

The REMNANT study will evaluate whether treating minimal residual disease (MRD) relapse after first line treatment prolongs progression free survival and overall survival for myeloma patients versus treating relapse after first line treatment at progressive disease. To establish a homogenous group of MRD negative patients after first line treatment including autologous stem cell transplantation, patients are enrolled at diagnosis and treated with Norwegian standard of care first line treatment. MRD negative patients will move on to the randomized part.

Key facts

Study ID

NCT04513639

Run by

Oslo University Hospital

People needed

176

Starts

2020-08-27

Expected to finish

2032-06-01

Last updated by the study team

2025-03-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Ålesund Hospital — Ålesund, Norway (enrolling)
• Haukeland University Hospital — Bergen, Norway (enrolling)
• Nordland Hospital Bodø — Bodø, Norway (enrolling)
• Sykehuset Ostfold — Fredrikstad, Norway (enrolling)
• Førde Central Hospital — Førde, Norway (enrolling)
• Sørlandet Hospital Kristiansand — Kristiansand, Norway (enrolling)
• Levanger Hospital — Levanger, Norway (enrolling)
• Akershus University Hospital — Lørenskog, Norway (enrolling)
• Oslo University Hospital — Oslo, Norway (enrolling)
• Helse Stavanger HF — Stavanger, Norway (enrolling)
• University Hospital North Norway — Tromsø, Norway (enrolling)
• St. Olavs Hospital — Trondheim, Norway (enrolling)
• The Hospital of Vestfold — Tønsberg, Norway (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.